UK-based private artificial intelligence (AI) company BenevolentAI, in collaboration with the Association of Medical Research Charities (AMRC), has created a new award to help charities support their medical research and develop new potential treatments and therapies using AI.

The prize, known as the BenevolentAI Award, will be given to a single applicant once every year.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The winner of the award will have access to the company’s latest technology platform, through which the selected charity will be able to resolve specific research-based challenges.

The company’s platform can be used for conducting deep investigation in a specific disease, developing a better understanding of the disease, identifying new areas and approaches in research and development (R&D) and boosting research towards new treatments and cures.

The award judging panel will comprise BenevolentAI bioscience subsidiary BenevolentBio CEO Jackie Hunter and AMRC CEO Aisling Burnand.

“Most scientific breakthroughs are made by analysing data, but we live in a world where vast quantities of data make the discovery of new drugs and treatments for disease very difficult.”

Hunter said: “Most scientific breakthroughs are made by analysing data, but we live in a world where vast quantities of data make the discovery of new drugs and treatments for disease very difficult.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

“We use AI to solve this issue and want to offer medical research charities the chance to benefit from the successes we have had a company in developing, validating and commercialising this technology.”

The applications for the BenevolentAI Award need to be submitted by 31 January next year and can be filed by all AMRC member medical charities, big and small, and in any disease area.

The applications should focus on addressing a specific problem and/or advancing a specific initiative.

The judging panel will access applications and choose the winning charity to be announced on 20 March 2018.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Imagene’s Oncology Intelligence (OI) Suite has won the Innovation Award for Precision Oncology, for transforming how pharma designs and runs oncology trials. From AI-driven biomarker discovery to smarter patient stratification, see how Imagene is cutting time, cost and risk in cancer drug development.

Discover the Impact